# Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

> **NCT01367158** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 440 (actual)

## Conditions studied

- Meningococcal Disease
- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine
- **BIOLOGICAL:** Meningococcal (group B) multicomponent recombinant adsorbed vaccine
- **BIOLOGICAL:** Tdap

## Key facts

- **NCT ID:** NCT01367158
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-07
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2014-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01367158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01367158, "Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01367158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*